

1. For the 4-month period from September to December 2020, how many patients has your trust treated with the following anti-VEGF treatments:

Please note data on the number of patients is not held in a reportable or centralised format, the data below relates to the number dispensed.

- Aflibercept 588
- Bevacizumab 98
- Brolucizumab Not in data
- Dexamethasone 46
- Fluocinolone acetonide Not in data
- Ranibizumab 118

2. Within your trust how many **intra-vitreous injections/implants** of each of the following treatments have been used in the four-month period from September to December 2020:

- Aflibercept 11
- Bevacizumab 13
- Brolucizumab Not in data
- Dexamethasone 46
- Fluocinolone Not in data
- Ranibizumab 118

3. If your trust is able to identify **intra-vitreous injections/implants** by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:

Wet Age Related Macular Degeneration (wAMD)

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

Diabetic Macular Oedema (DMO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

This information is not held in a reportable or centralised format; therefore this request is refused under section 17 of FOISA.